Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. - Wikidata - awgldk - TriplyDB

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

http://www.wikidata.org/entity/Q34737143

about

Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis Tuberculous meningitis: diagnosis and treatment overview.Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.A physiologically based pharmacokinetic model of rifampin in mice.Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux Challenges and opportunities in developing novel drugs for TB.Improving the tuberculosis drug development pipeline.Nonclinical models for antituberculosis drug development: a landscape analysis.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.The long and winding road to inhaled TB therapy: not only the bug's fault.NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans.Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.Protective and therapeutic effects of the resuscitation-promoting factor domain and its mutants against Mycobacterium tuberculosis in mice.Reply to "Contradictory results with high-dosage rifamycin in mice and humans".Whole cell screen of fragment library identifies gut microbiota metabolite indole propionic acid as antitubercular.Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.Improving treatment outcome assessment in a mouse tuberculosis model.

P2860

Q33589762-13E89E37-E6C8-4562-A7E4-4D4F8E085C65 Q34092117-B05CA0B8-12D8-4CAA-A2E3-4C33A655FFE5 Q35598474-3EDC5E30-90F1-428E-97AA-09998D0A6F8B Q35910242-CEAA7757-2D7E-4806-87CA-CAAA5E38C7A7 Q36018542-5BB64418-CA21-419A-A900-FB87681D0D10 Q36018624-9826E025-59A6-4D9B-B39D-B22731E8154F Q36056408-5A67F3D7-7ECA-4442-B271-6B58F0482231 Q36082913-B4EA6FD8-03B3-4514-82F7-114E67B878F3 Q36086381-10DD1A86-46D1-4987-8C57-23B7AA54FD0C Q36109585-DAC0EBB8-177A-4945-BACE-3624BC33D0AA Q36757635-4F5B955E-95BE-44D5-9D5A-3DD1C9F8A1D7 Q37119985-F2FEA3CF-5052-48AB-A1A6-D7F3D6BA1AD8 Q37138650-4CF79D31-B054-428A-B780-9979FE418132 Q37679508-1760DFC6-3520-46F5-9498-D35984A542BA Q37924294-BC103F8F-DB4D-4102-B9E4-F6A42B37038F Q38378647-53380F9E-0345-4B97-BA53-A1D4690738EA Q38502294-BBE137DA-490A-424F-BCA9-55BDE5E836D7 Q38754367-1191F02D-E400-45A1-BBF3-87BDD74DFC2C Q38782463-5802BC21-4029-41E8-9031-DB3C9F012681 Q40087530-D8B8A0F6-9818-4346-A203-729FCC20F5D8 Q40363572-F5F0CA0B-4403-4C53-919F-6EDD83CCCB69 Q41280396-886CBF2C-5445-4559-AC2A-286CC6453795 Q41447524-0C2D6987-6D1D-459F-95C6-6A7D211A7E41 Q42952085-303D788A-E484-42D9-BD3E-A65B4664B8E1 Q49921691-42490243-E591-4A93-AB64-AA0C93785890 Q52584723-5EF65D0F-2846-46AC-AB76-8A8217F380E1 Q54239058-E46D16CB-44A2-4EB5-B66C-90525F8AC9EA

P2860

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

http://www.wikidata.org/entity/Q34737143

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@ast

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@en

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@nl

type

label

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@ast

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@en

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@nl

prefLabel

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@ast

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@en

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@nl

P1433

Q34737143-E7F6989B-A7C8-407E-A83C-864A1A951B70

P1476

Q34737143-77B9CE42-1DB9-40EE-B7A5-DEE64E90B5CD

P2093

Q34737143-1B1481BD-100A-4113-B1D6-1EDE0136F533

Q34737143-228D48F4-9178-47EE-A21C-F5411440DF6C

Q34737143-41E72045-6CF7-444F-A78C-A653FC46DD40

Q34737143-56DFC8F5-0720-4F82-8F71-B663CE0A9EA6

Q34737143-72441F6B-1AD1-4A5A-9464-6AA885D03A1A

Q34737143-8922C440-AB96-4C7F-81A0-2BF846F2AF25

Q34737143-C802B892-3F97-4BB1-9FC8-7A4C1098868C

Q34737143-D21F45A3-4C2F-4CA9-83A8-15C290615388

Q34737143-FBE18B5B-0099-49D6-9DD0-630F595DD23A

P2860

Q34737143-0C0F255D-2A09-42B2-907E-F0A113E51946

Q34737143-0C6C514F-FFF7-40D9-878F-2F301EC318C4

Q34737143-1633C9AB-9658-48AA-85CA-C07CF03F1E58

Q34737143-17534726-F41E-4C41-B69D-1357340DE715

Q34737143-1C387FB7-EF46-4F47-BD11-6134DE935E30

Q34737143-1E184E07-30D3-4874-9263-F54A4765239C

Q34737143-1E9C3A17-4FAF-4AAC-8302-F7665D16F611

Q34737143-25B55D7C-BD17-4069-934E-04E960DEF2B0

Q34737143-27EAEAF5-9573-4C51-9663-41ABA69A5A0E

Q34737143-28C154C9-EB1E-462A-BB21-A93997B99DCD

P304

Q34737143-C71A48A9-BA52-473A-A970-B37B5D91291D

P31

Q34737143-950F79E4-46C0-4495-9115-0A459910BA78

P356

Q34737143-7828FE0F-A2A2-4E6B-9737-397B802A27FC

P407

Q34737143-BAA1C2B0-93BB-424B-89A7-D12840BAEBC6

P433

Q34737143-44910F7A-2527-497E-A82E-8F2213DF9AE3

P478

Q34737143-80C29FF7-1A35-4AC8-B73F-B16E9B73CD4F

P577

Q34737143-EAD68156-6B9C-4AC0-8643-CA76B845152C

P698

Q34737143-F67A9E98-532D-4C48-B109-0A841F6FDFC1

P921

Q34737143-9D094D27-C19D-4648-AC37-9AA34A27C52E

P932

Q34737143-BFA377FF-A46C-4E85-B14E-ED40D947AAF4

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparative studies evaluating ...... st Mycobacterium tuberculosis.

@en

P2093

Anne J Lenaerts

http://www.w3.org/2001/XMLSchema#string

Charles A Peloquin

http://www.w3.org/2001/XMLSchema#string

Colby L Wells

http://www.w3.org/2001/XMLSchema#string

Elizabeth J Brooks

http://www.w3.org/2001/XMLSchema#string

Ian M Orme

http://www.w3.org/2001/XMLSchema#string

Janet C Gilliland

http://www.w3.org/2001/XMLSchema#string

Lisa K Woolhiser

http://www.w3.org/2001/XMLSchema#string

Mary A De Groote

http://www.w3.org/2001/XMLSchema#string

Veronica Gruppo

http://www.w3.org/2001/XMLSchema#string

P2860

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.

Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis.

Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

P304

1237-1247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00595-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21135176

http://www.w3.org/2001/XMLSchema#string

P921

Mycobacterium tuberculosis

P932

3067068

http://www.w3.org/2001/XMLSchema#string